Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study. (1st February 2022)

• Record Type: Journal Article
• Authors: Jin, Meng; Chen, Can; Huang, Jinyu; Zhang, Fengqin; Dong, Tianyi; Zhang, Ming; Yue, Huihui; Liu, Kui; Li, Guangcai; Hu, Ke; Zhang, Huilan
• Is Part Of: Journal of asthma. Volume 59:Number 2(2022)
• Page Start: 230
• Page End: 238
• Publication Date: 2022-02-01
• Subjects: COVID-19 -- asthma -- D-dimer -- procalcitonin; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2020.1850768
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Objective: Although it is reported that patients with coronavirus disease 2019 (COVID-19) disease who have comorbidities are at higher risk to suffer adverse clinical outcomes, there are inadequate evidence to clarify the association between COVID-19 and asthma. On this ground, this study aims to systematically analyze the clinical characteristics of COVID-19 patients with asthma. Methods: In this single-center, retrospective and observational cohort study, 21 COVID-19 patients with asthma and 100 non-asthma COVID-19 patients were statistically matched by propensity score based on age, sex and comorbidities. Meanwhile, a collection and comparison concerning demographic indicators, clinical and laboratory examinations, treatments and outcomes were conducted between two groups to specify their differences. Results: Statistically, the COVID-19 patients with asthma had a higher proportion of ICU admission (14.3% [3/21] vs. 2.1% [2/96] p = 0.040) than those who do not have. On top this, a higher level of inflammatory responses, such as interleukin 6, interleukin 8, procalcitonin, leukocytes, neutrophils and CD4 + T cells was presented in asthma patients. Moreover, the increase of organ damage indices like D-dimer, lactate dehydrogenase and high-sensitivity cardiac troponin I, were more pronounced in COVID-19 patients with asthma. Conclusions: Exacerbated inflammatory responses and multiple organ damages were triggered in COVID-19 patients with asthma, which highlights more intensive surveillance and supportive treatment.